GURUFOCUS.COM » STOCK LIST » USA » NAS » ITeos Therapeutics Inc (NAS:ITOS) » Definitions » EV-to-EBITDA
Switch to:

ITeos Therapeutics (NAS:ITOS) EV-to-EBITDA

: -0.01 (As of Today)
View and export this data going back to 2020. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ITeos Therapeutics's enterprise value is $-3.5 Mil. ITeos Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 was $326.0 Mil. Therefore, ITeos Therapeutics's EV-to-EBITDA for today is -0.01.

The historical rank and industry rank for ITeos Therapeutics's EV-to-EBITDA or its related term are showing as below:

ITOS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.43   Med: 0.99   Max: 20.15
Current: -0.01

During the past 4 years, the highest EV-to-EBITDA of ITeos Therapeutics was 20.15. The lowest was -0.43. And the median was 0.99.

ITOS's EV-to-EBITDA is ranked better than
98.49% of 531 companies
in the Biotechnology industry
Industry Median: 3.38 vs ITOS: -0.01

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2022-12-02), ITeos Therapeutics's stock price is $20.03. ITeos Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $6.890. Therefore, ITeos Therapeutics's PE Ratio for today is 2.91.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


ITeos Therapeutics (NAS:ITOS) EV-to-EBITDA Historical Data

The historical data trend for ITeos Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ITeos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21
EV-to-EBITDA - - -21.89 3.16

ITeos Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.07 3.16 0.83 -0.13 -0.21

ITeos Therapeutics (NAS:ITOS) EV-to-EBITDA Competitive Comparison

For the Biotechnology subindustry, ITeos Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

ITeos Therapeutics (NAS:ITOS) EV-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, ITeos Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ITeos Therapeutics's EV-to-EBITDA falls into.



ITeos Therapeutics EV-to-EBITDA Calculation

ITeos Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-3.512/326.031
=-0.01

ITeos Therapeutics's current Enterprise Value is $-3.5 Mil.
ITeos Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $326.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ITeos Therapeutics  (NAS:ITOS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

ITeos Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=20.03/6.890
=2.91

ITeos Therapeutics's share price for today is $20.03.
ITeos Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.890.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


ITeos Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ITeos Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


ITeos Therapeutics (NAS:ITOS) Business Description

ITeos Therapeutics logo
Traded in Other Exchanges
N/A
Address
139 Main Street, Cambridge, MA, USA, 02142
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
Executives
Ho Tony W director CRISPR THERAPEUTICS AG 610 MAIN STREET CAMBRIDGE MA 02139
Iannone Robert director 300 THE AMERICAN WAY MORRIS PLAINS NJ 07950
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET 18TH FLOOR BOSTON MA 02116
Roden Matthew director 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Asset Management Investors Bv2014 Llc 10 percent owner C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2014 Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2014 Gp Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Dirocco Derek director 535 MISSION STREET 14TH FLOOR SAN FRANCISCO CA 94105
Mpm Bioventures 2018 (b), L.p. 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2018, L.p. 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Asset Management Investors Bv2018 Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2018 Gp Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2018 Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Gall Matthew officer: Chief Financial Officer C/O ITEOS THERAPEUTICS, INC. 139 MAIN STREET CAMBRIDGE MA 02142

ITeos Therapeutics (NAS:ITOS) Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership